Russell Investments Group Ltd. Has $33.45 Million Position in Supernus Pharmaceuticals, Inc. (SUPN)

Russell Investments Group Ltd. reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 18.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 836,340 shares of the specialty pharmaceutical company’s stock after selling 184,420 shares during the period. Russell Investments Group Ltd. owned approximately 1.65% of Supernus Pharmaceuticals worth $33,453,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Pinebridge Investments L.P. raised its holdings in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after purchasing an additional 86 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System raised its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after purchasing an additional 128 shares in the last quarter. Finally, CS Mckee LP raised its holdings in Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after purchasing an additional 200 shares in the last quarter. 94.70% of the stock is owned by hedge funds and other institutional investors.

In other news, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 150,000 shares of company stock valued at $7,055,350. 6.70% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at $38.70 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $20.55 and a 1-year high of $50.04. The stock has a market cap of $1,953.09, a PE ratio of 35.94, a price-to-earnings-growth ratio of 1.61 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts predict that Supernus Pharmaceuticals, Inc. will post 1.07 EPS for the current fiscal year.

Several research analysts recently issued reports on the stock. B. Riley reissued a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a report on Monday. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, November 7th. SunTrust Banks, Inc. reissued a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Finally, Piper Jaffray Companies set a $41.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, October 29th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $49.60.

TRADEMARK VIOLATION WARNING: “Russell Investments Group Ltd. Has $33.45 Million Position in Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/22/russell-investments-group-ltd-has-33-45-million-position-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply